Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced BRAF-mutant Cancers × PX-866 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hereditary Sensory and Autonomic Neuropathies 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced BRAF-mutant Cancers 1

Interventions

Vemurafenib 1 PX-866 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01616199 2018-05-16

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Seagen Inc.

Phase 1/2 Terminated

Advanced BRAF-mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡